By taking advantage of gene engineering,recombinant calcitonin analogue can be successfully obtained.This method can greatly improve the biological activity of the analogue of calcitonin and lower its antigenicity.In this review we discuss the recent progress in the production of recombinant human calcitonin.

Objective To study and analyze the clinical efficacy of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure. Methods 80 patients with coronary heart disease and heart failure treated in our hospital from January 2015 to December 2016 were selected and randomly divided into the control group and the experimental group, with 40 cases in each group. The control group received routine treatment, including diuretics and angiotensin converting enzyme inhibitors, and the experimental group was treated with trimetazidine combined with metoprolol. The therapeutic effects of the two groups were compared and analyzed. Results After the corresponding treatment, 5 patients in the experimental group were invalid. In the control group, 14 patients were ineffective. The effective rate of treatment in the experimental group (87.5％) was significantly higher than that in the control group (65.0％), the differences were statistically significant (P<0.05). After treatment, the LVEF in the experimental group was (50.4 ± 7.7)％, and the LVEF in the control group was (45.1 ± 7.0)％. In addition, the LVEDD and LVESD indexes and LVEF in the experimental group were better than those in the control group, the differences were statistically significant (P<0.05). Conclusion The clinical effect of trimetazidine combined with metoprolol in the treatment of coronary heart disease and heart failure is better. It can improve the efficiency of treatment to some extent, and has the significance of further promotion and application.

Background and purpose:Advanced pancreatic cancer is characteristic of poor treatment eff icacy and short survival time. Gemcitabine is considered as front-line therapy for advanced pancreatic cancer. Gemcitabine combinations have shown a favorable impact on survival. We compared gemcitabine-based combination cheme therapy and gemcitabine(GEM) alone in patients with advanced pancreatic cancer through Meta analysis in phase Ⅲ clinical trials. Methods:MEDLINE and EMBASE searches were supplemented by information from trial registers of phase Ⅲ randomized controlled trials(RCTs) for GEM-based combination therapy and GEM alone for advanced pancreatic cancer. A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available RCTs. The Meta-analysis involved 6-months and 1-year survival rate and objective remission rate(ORR) . Results:The Meta-analysis included 20 RCTs. The result of our Meta-analysis showed that there was signifi cant improvement in the GEM combination group with regard to the 1-year survival rate(RR:0.87,95%:(0.78,0.96) ,P=0.008) . The other result of our meta-analysis showed no signifi cant difference between two groups. Conclusion:GEM-based combination therapy may be effective with regard to the survival rate compared with GEM alone.

After ig and iv 3H-berberine in rabbits, the plasma radioactivity-time cure was found to be 2-compartment open model. The pharma-cokinetic parameters were: T1/2B 35 .3?1 .3h ( ig ) and 35.8 ? 2.0h (iv), Vd 20 ?3 L/kg(ig) & 22.1?1.7 L/kg ( iv ) . 3H-berberine was rapidly absorbed & taken up by various organs . The highest radioactivity was found in lung, followed by liver, spleen & heart. The rate of binding with plasma protein was 38 ? 3 % . In 6 d cumulative excretion of radioactivity was 73% of total dose in urine & 10.9% in fe-ces . 3H-berberine was excreted mainly in unchanged form, as measured by TLC & liquid scintillation counting in urine & bile.

Objective To investigate the effect of granulocyte-macrophage colony-stimulating factor(GM-CSF) on rat calcitonin(CT).Methods A total of 48 SD healthy rats were randomly divided into control group,low GM-CSF(10?g/kg?d) and high GM-CSF dosage(50?g/kg?d) groups.The rats in experimental groups were continuously treated by an intraperitoneal application of GM-CSF for over 7 days.The level of calcitonin was measured by radioimmunoassay(RIA),and the serum calcium(Ca),ALP and phosphorus(P) were examined by biochemical method.Results The level of the serum calcium in high-dosage GMCSF group was lower than that in the control group(P0.05).Conclusion The high dosage GM-CSF can decrease the serum calcium;the low-and high-dosage GM-CSF can decrease the serum calcitonin,but has no effect on the level of serum phosphorus and ALP.

Objective Celloidin sections of temporal bone were used to develop a serial stereo anatomical atlas of temporal bone by computer aided three dimensional(3-D) reconstruction and stereology. Methods Fifty sets of serial celloidin sections of temporal bone with reference points were prepared and 3-D morphology of structures in temporal bone was restored systemically by the technique of computer aided 3-D reconstruction. A system of stereo anatomical atlas of temporal bone with stereoscope was established. Results Totally 48 cases of reconstruction were accomplished for bony and membranous labyrinth, ossicles, tendons, facial nerve and its canal, round window membrane and niche, posterior ampullary nerve, endolymphatic sac, cochlear aqueduct, VII and VIIIth cranial nerve. The stereo picture pairs of these structures with the best representation were selected as the stereo anatomical atlas of temporal bone which showed the fine spatial morphology and relationship of the above structures. The stereo anatomical atlas was applied to guide ear surgery and to assist anatomic training of temporal bone. Conclusion The stereo anatomic atlas of temporal bone is an innovative powerful anatomic tool and has tremendous application futures in otology, or even in the whole medical science.

Objective To establish an HPLC method for the determination of plasma metformin hydrochloride and an HPLC/ESI-MS method for the determination of plasma glibenclamide in human. Methods The metformin plasma samples were added with acetonitrile to denature proteins and the supernatant was injected into the system directly by using EC 250/4.6 NUCLEOSIL 100-5 analytical column (4.6 mm?250 mm, 5 ?m) with a mobile phase of 0.03 mol/L (NH 4) H 2PO 4∶acetonitrile (75∶25, pH 7.0) at the flow rate of 1.0 ml/min and the detection wavelength of 240 nm. Using glipizide as a internal standard, the glibenclamide plasma samples were extracted with ethyl acetate and determined by LC-MS using a chromatographic column ORBAX SB300C 18 (2.1 mm?150 mm, 5 ?m) with a mobile phase of acetonitrile-0.1% ammonium acetate (55∶45, V/V) at the flow of 0.2 ml/min. Results The glibenclamide concentration had a good linear correlation in the range of 2-200 ng/ml (r=0.999 8) while the metformin concentration in the range of 6.25-4 000 ng/ml (r= 0.999 9 ). Both the inter-day and intra-day RSD of metformin and glibenclamide were lower than 5%. Conclusion The assays have been proved to be sensitive, accurate and convenient and can be used in the study of human pharmacokinetics of glibenclamide and metformin hydrochloride.

Objective To observe the effects and significance of Nordy on the expression of vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) in the retinas of diabetic rats. Methods Diabetic rats by streptozotocin were randomly divided into diabetes group (5 rats?2) and Nordy treatment group (5 rats?2). Another 10 normal rats were recruited as normal control group. The Nordy treatment group was injected 0.5% Nordy (27 mg/kg) while diabetes groups and normal control group were injected saline solution into peritoneal cavity once every other day. One month or 3 months later, 5 rats in each group were killed and the expression of VEGF and iNOS in the retinas were detected by immunohisochemistry. The average positive areas were measured and analyzed by computer aided video system. Results The expression of VEGF and iNOS in control group were extremely low. In 1 month, the expression of VEGF and iNOS in diabetic group increased and the average positive areas of VEGF and iNOS were significantly more than that of Nordy treatment group (P

Objective We sought to investigate the attitude to the evaluation of nursing undergraduate innovative talents quality by post audience and undergraduate nursing students and to provide reference for the cultivation of innovative talents and quality standard construction.Methods Using convenient sampling method,we selected the medical staff,patients and junior undergraduate nursing students as the research object.A questionnaire survey on the nursing undergraduate innovative talents quality evaluation was carried out.Results The attitude to nursing undergraduate innovative talents quality evaluation from high to low was physicians,nurses,hospital patients and junior undergraduate nursing students.Different populations had different expectations for nursing undergraduate innovative talents.Conclusions To cultivate the nursing undergraduate innovative talents,we should not only focus on the ability of nursing scientific research and innovation,but also should be based on the moral and occupation quality.Only giving full consideration to demands and expectations of the nursing undergraduate innovative talents by all post audience,can we evaluate the talent quality more professionally,scientifically and systematically.

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the Western world,and is potentially curable with standard R-CHOP chemoimmunotherapy. We are now in an era that the heterogeneity of DLBCL is defined genetically and molecularly,and rational subset-specific therapeutic targets are guiding clinical trials.Primary mediastinal DLBCL is a unique clinicopathologic entity, and alternatives to R-CHOP may confer superior outcome. Rearrangement of the myc oncogene occurs in 10%of patients with DLBCL, and confers a very poor prognosis with standard R-CHOP, particularly when there is concomitant rearrangement of bcl-2, a condition referred to as double-hit DLBCL. A larger subset of DLBCL demonstrates overexpression of both myc and bcl-2 by immunohistochemistry. Analyze the source of cells by gene expression profile, immunohistochemistry algorithms,or a novel Lymph2Cx platform,provides prognostic information, and guides therapeutic decisions in both relapsed and de novo disease. This article reviews latest research presented at the 57th American Society of Hematology (ASH) annual meeting on the definition of specific subsets of DLBCL and selection of subtype-specific treatment,including novel approaches under investigation. Understanding these key features of the pathology report, and limitations of these assays defining subsets of DLBCL, allows for a precision medicine approach to this disease.